Drug Use-Results Survey of Erbitux (Injection 100 mg) for EGFR-Positive, Curatively Unresectable Advanced or Recurrent Colorectal Cancer Patients

Primary outcome(s): (Safety) 1-1. Profile of ADRs/infections reported (types, grades, and incidence rates, etc.) 1-2. Factors potentially affecting the safety of Erbitux (analyzing the types and incidence rates of ADRs/infections by patient demographic and baseline characteristics)